Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q2

7459.TEDINET S100S94Y
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥3.36T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥65.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥38.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.82Tat 2023-09-30Cons.Assets
Total assets¥1.71Tat 2023-03-31Cons.Assets
Total assets¥1.74Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.10Tat 2023-09-30Cons.Liabilities
Total liabilities¥1.02Tat 2023-03-31Cons.Liabilities
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets
Net assets / equity¥688.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥209.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥195.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥39.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥43.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.082023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥184.822022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥179.122022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
Other elCurrentYTDDuration8000000JPY
Extraordinary lossPrior1YTDDuration3566000000JPY
Extraordinary lossCurrentYTDDuration105000000JPY
Income before income taxesPrior1YTDDuration33342000000JPY
Income before income taxesCurrentYTDDuration32840000000JPY
Income taxes currentPrior1YTDDuration15829000000JPY
Income taxes currentCurrentYTDDuration16677000000JPY
Income taxes deferredPrior1YTDDuration-4391000000JPY
Income taxes deferredCurrentYTDDuration-6370000000JPY
Income taxesPrior1YTDDuration11438000000JPY
Income taxesCurrentYTDDuration10306000000JPY
Profit lossPrior1YTDDuration21904000000JPY
Profit lossCurrentYTDDuration22533000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration4579000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration5379000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration17324000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration17154000000JPY
Profit lossPrior1YTDDuration21904000000JPY
Profit lossCurrentYTDDuration22533000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration8909000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration7205000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration5000000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration209000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-249000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration108000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration1103000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration826000000JPY
Other comprehensive incomePrior1YTDDuration9769000000JPY
Other comprehensive incomeCurrentYTDDuration8349000000JPY
Comprehensive incomePrior1YTDDuration31673000000JPY
Comprehensive incomeCurrentYTDDuration30883000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration26487000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration24636000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration5186000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration6246000000JPY
Income before income taxesPrior1YTDDuration33342000000JPY
Income before income taxesCurrentYTDDuration32840000000JPY
Depreciation and amortization ope cfPrior1YTDDuration7065000000JPY
Depreciation and amortization ope cfCurrentYTDDuration8221000000JPY
Amortization of goodwill ope cfPrior1YTDDuration127000000JPY
Amortization of goodwill ope cfCurrentYTDDuration526000000JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration-57000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration-481000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration571000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-56000000JPY
Increase decrease in provision for loss on disaster ope cfPrior1YTDDuration-405000000JPY
Increase decrease in provision for loss on disaster ope cfCurrentYTDDuration－JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration105000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-29000000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration-27262000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass